These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32 related articles for article (PubMed ID: 2138994)
1. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia. Ramakrishnan R; Munir F; Quesada AE; Hitzler J; Cuglievan B Pediatr Blood Cancer; 2024 Jun; 71(6):e30974. PubMed ID: 38523255 [No Abstract] [Full Text] [Related]
2. Presentation of M4 acute myeloid leukemia in anuric renal failure with hyperuricemia and enlarged kidneys. Duda J; Zoger S J Pediatr Hematol Oncol; 2002 Jan; 24(1):55-8. PubMed ID: 11902742 [TBL] [Abstract][Full Text] [Related]
3. Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. Hemminki K; Zitricky F; Försti A; Kontro M; Gjertsen BT; Severinsen MT; Juliusson G Blood Cancer J; 2024 Mar; 14(1):44. PubMed ID: 38480693 [No Abstract] [Full Text] [Related]
4. Long-Term Effects of Acute Myeloid Leukemia Treatment on the Oral System in a Pediatric Patient. Lupi SM; Rodriguez Y Baena A; Cervino G; Todaro C; Rizzo S Open Dent J; 2018; 12():230-237. PubMed ID: 29760815 [TBL] [Abstract][Full Text] [Related]
5. Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy. Witteveen EO; Verdonck LF; Nieuwenhuis HK; Dekker AW Haematol Blood Transfus; 1990; 33():309-13. PubMed ID: 2323635 [No Abstract] [Full Text] [Related]
6. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Grier HE; Gelber RD; Clavell LA; Camitta BM; Link MP; Garcea MJ; Weinstein HJ Haematol Blood Transfus; 1990; 33():193-7. PubMed ID: 2182411 [No Abstract] [Full Text] [Related]
8. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. Jehn U; Heinemann V Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134 [TBL] [Abstract][Full Text] [Related]
9. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83. Ritter J; Creutzig U; Schellong G Haematol Blood Transfus; 1990; 33():185-92. PubMed ID: 2182410 [No Abstract] [Full Text] [Related]
10. High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia. Lie SO; Berglund G; Gustafsson G; Jonmundsson G; Siimes M; Yssing M Haematol Blood Transfus; 1990; 33():215-21. PubMed ID: 2138994 [No Abstract] [Full Text] [Related]